Share on StockTwits
 

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Joseph L. Goldstein unloaded 1,000 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $320.62, for a total transaction of $320,620.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $641,240. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.06% on Thursday, hitting $326.98. 1,154,416 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $331.64. The stock’s 50-day moving average is $285. and its 200-day moving average is $280.. The company has a market cap of $32.118 billion and a price-to-earnings ratio of 45.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The company’s revenue for the quarter was up 47.0% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $4.95 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on REGN shares. Analysts at Oppenheimer downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. They now have a $325.00 price target on the stock, up previously from $310.00. They noted that the move was a valuation call. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $344.00 to $348.00 in a research note on Thursday. Finally, analysts at Goldman Sachs raised their price target on shares of Regeneron Pharmaceuticals from $353.00 to $383.00 in a research note on Thursday. They now have a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $315.85.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.